Comparison of helper containing and helper free HSV amplicon vectors for immune therapy of CLL

Khaled Tolba, William Bowers, Shannon Hilchey

Research output: Contribution to journalArticle

Abstract

HSV-based vectors have several biologic features well suited for gene therapy of leukemia/lymphoma. These include a high transduction efficiency, an ability to infect post-mitotic cells and a large packaging capacity. We have studied Herpes Simplex virus (HSV) based amplicon vectors for transduction of primary B-cell chronic lymphocytic leukemia (CLL). Three HSV amplicon vectors were constructed encoding b-galactosidase (lac), CD80 (B7.1) or CD154 (CD40L) and were packaged using either standard helpervirus packaging methods (HSVlac, HSVB7.1 and HSVCD40L, respectively) or a helper virus-free packaging method (hf-HSVlac, hf-HSVB7.1 and hf-HSVCD40L, respectively), based on the use of a bacterial artificial chromosome (BAC) system. CLL cells were transduced with either HSV or hf-HSV amplicons and studied for the ability to stimulate T-cell proliferation in an allogeneic mixed lymphocyte reaction (MLTR). At a multiplicity of infection (MOI) that transduced 60-90% of the CLL cells, a vigorous T-cell proliferative response was obtained using cells transduced with helper-free HSV amplicon (hf-HSVB7.1 ) but not with helper-containing HSVB7.1. Extrinsic provision of signal one partially restored the T-cell proliferative response to cells transduced with helper-containing HSVB7.1 stocks suggesting that one or more proteins encoded by the helper virus might affect antigen presentation. CLL cells transduced with either HSV-CD40L or hf-HSV-CD40L were compared for their ability to up-regulate B7.1 and function as T-cell stimulators in MLTR. Direct comparison of the two amplicon vectors revealed significantly better B7.1 expression in response to transduction with hf-HSV-CD40L compared to HSV-CD40L. CLL cells transduced with hf-HSV-CD40L were consistently more effective at stimulating allogeneic T-cell proliferative response than those transduced with HSV-CD40L. CLL cells transduced with helper-containing HSV amplicons showed a reduction of MHC-I expression on transduced cells, impaired capacity to respond to CD40 activation and decreased expression of CD 19 compared to cells transduced with hf-HSV amplicons. This may account for the decreased immune stimulatory function of CLL cells transduced with helper-containing HSV amplicons. We conclude that helper-free HSV amplicons represent a logical choice for immune-based clinical trials.

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART I
StatePublished - Dec 1 2000

Fingerprint

Simplexvirus
B-Cell Chronic Lymphocytic Leukemia
Viruses
CD40 Ligand
T-cells
Therapeutics
T-Lymphocytes
Helper Viruses
Mixed Lymphocyte Culture Test
Packaging
Product Packaging
Lymphocytes
Galactosidases
Bacterial Artificial Chromosomes
Virus Assembly
Gene therapy
Antigen Presentation
Cell proliferation
Genetic Therapy
Chromosomes

ASJC Scopus subject areas

  • Hematology

Cite this

Comparison of helper containing and helper free HSV amplicon vectors for immune therapy of CLL. / Tolba, Khaled; Bowers, William; Hilchey, Shannon.

In: Blood, Vol. 96, No. 11 PART I, 01.12.2000.

Research output: Contribution to journalArticle

Tolba, K, Bowers, W & Hilchey, S 2000, 'Comparison of helper containing and helper free HSV amplicon vectors for immune therapy of CLL', Blood, vol. 96, no. 11 PART I.
Tolba, Khaled ; Bowers, William ; Hilchey, Shannon. / Comparison of helper containing and helper free HSV amplicon vectors for immune therapy of CLL. In: Blood. 2000 ; Vol. 96, No. 11 PART I.
@article{0885158d08e24f6a9be63f26fcaa5495,
title = "Comparison of helper containing and helper free HSV amplicon vectors for immune therapy of CLL",
abstract = "HSV-based vectors have several biologic features well suited for gene therapy of leukemia/lymphoma. These include a high transduction efficiency, an ability to infect post-mitotic cells and a large packaging capacity. We have studied Herpes Simplex virus (HSV) based amplicon vectors for transduction of primary B-cell chronic lymphocytic leukemia (CLL). Three HSV amplicon vectors were constructed encoding b-galactosidase (lac), CD80 (B7.1) or CD154 (CD40L) and were packaged using either standard helpervirus packaging methods (HSVlac, HSVB7.1 and HSVCD40L, respectively) or a helper virus-free packaging method (hf-HSVlac, hf-HSVB7.1 and hf-HSVCD40L, respectively), based on the use of a bacterial artificial chromosome (BAC) system. CLL cells were transduced with either HSV or hf-HSV amplicons and studied for the ability to stimulate T-cell proliferation in an allogeneic mixed lymphocyte reaction (MLTR). At a multiplicity of infection (MOI) that transduced 60-90{\%} of the CLL cells, a vigorous T-cell proliferative response was obtained using cells transduced with helper-free HSV amplicon (hf-HSVB7.1 ) but not with helper-containing HSVB7.1. Extrinsic provision of signal one partially restored the T-cell proliferative response to cells transduced with helper-containing HSVB7.1 stocks suggesting that one or more proteins encoded by the helper virus might affect antigen presentation. CLL cells transduced with either HSV-CD40L or hf-HSV-CD40L were compared for their ability to up-regulate B7.1 and function as T-cell stimulators in MLTR. Direct comparison of the two amplicon vectors revealed significantly better B7.1 expression in response to transduction with hf-HSV-CD40L compared to HSV-CD40L. CLL cells transduced with hf-HSV-CD40L were consistently more effective at stimulating allogeneic T-cell proliferative response than those transduced with HSV-CD40L. CLL cells transduced with helper-containing HSV amplicons showed a reduction of MHC-I expression on transduced cells, impaired capacity to respond to CD40 activation and decreased expression of CD 19 compared to cells transduced with hf-HSV amplicons. This may account for the decreased immune stimulatory function of CLL cells transduced with helper-containing HSV amplicons. We conclude that helper-free HSV amplicons represent a logical choice for immune-based clinical trials.",
author = "Khaled Tolba and William Bowers and Shannon Hilchey",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART I",

}

TY - JOUR

T1 - Comparison of helper containing and helper free HSV amplicon vectors for immune therapy of CLL

AU - Tolba, Khaled

AU - Bowers, William

AU - Hilchey, Shannon

PY - 2000/12/1

Y1 - 2000/12/1

N2 - HSV-based vectors have several biologic features well suited for gene therapy of leukemia/lymphoma. These include a high transduction efficiency, an ability to infect post-mitotic cells and a large packaging capacity. We have studied Herpes Simplex virus (HSV) based amplicon vectors for transduction of primary B-cell chronic lymphocytic leukemia (CLL). Three HSV amplicon vectors were constructed encoding b-galactosidase (lac), CD80 (B7.1) or CD154 (CD40L) and were packaged using either standard helpervirus packaging methods (HSVlac, HSVB7.1 and HSVCD40L, respectively) or a helper virus-free packaging method (hf-HSVlac, hf-HSVB7.1 and hf-HSVCD40L, respectively), based on the use of a bacterial artificial chromosome (BAC) system. CLL cells were transduced with either HSV or hf-HSV amplicons and studied for the ability to stimulate T-cell proliferation in an allogeneic mixed lymphocyte reaction (MLTR). At a multiplicity of infection (MOI) that transduced 60-90% of the CLL cells, a vigorous T-cell proliferative response was obtained using cells transduced with helper-free HSV amplicon (hf-HSVB7.1 ) but not with helper-containing HSVB7.1. Extrinsic provision of signal one partially restored the T-cell proliferative response to cells transduced with helper-containing HSVB7.1 stocks suggesting that one or more proteins encoded by the helper virus might affect antigen presentation. CLL cells transduced with either HSV-CD40L or hf-HSV-CD40L were compared for their ability to up-regulate B7.1 and function as T-cell stimulators in MLTR. Direct comparison of the two amplicon vectors revealed significantly better B7.1 expression in response to transduction with hf-HSV-CD40L compared to HSV-CD40L. CLL cells transduced with hf-HSV-CD40L were consistently more effective at stimulating allogeneic T-cell proliferative response than those transduced with HSV-CD40L. CLL cells transduced with helper-containing HSV amplicons showed a reduction of MHC-I expression on transduced cells, impaired capacity to respond to CD40 activation and decreased expression of CD 19 compared to cells transduced with hf-HSV amplicons. This may account for the decreased immune stimulatory function of CLL cells transduced with helper-containing HSV amplicons. We conclude that helper-free HSV amplicons represent a logical choice for immune-based clinical trials.

AB - HSV-based vectors have several biologic features well suited for gene therapy of leukemia/lymphoma. These include a high transduction efficiency, an ability to infect post-mitotic cells and a large packaging capacity. We have studied Herpes Simplex virus (HSV) based amplicon vectors for transduction of primary B-cell chronic lymphocytic leukemia (CLL). Three HSV amplicon vectors were constructed encoding b-galactosidase (lac), CD80 (B7.1) or CD154 (CD40L) and were packaged using either standard helpervirus packaging methods (HSVlac, HSVB7.1 and HSVCD40L, respectively) or a helper virus-free packaging method (hf-HSVlac, hf-HSVB7.1 and hf-HSVCD40L, respectively), based on the use of a bacterial artificial chromosome (BAC) system. CLL cells were transduced with either HSV or hf-HSV amplicons and studied for the ability to stimulate T-cell proliferation in an allogeneic mixed lymphocyte reaction (MLTR). At a multiplicity of infection (MOI) that transduced 60-90% of the CLL cells, a vigorous T-cell proliferative response was obtained using cells transduced with helper-free HSV amplicon (hf-HSVB7.1 ) but not with helper-containing HSVB7.1. Extrinsic provision of signal one partially restored the T-cell proliferative response to cells transduced with helper-containing HSVB7.1 stocks suggesting that one or more proteins encoded by the helper virus might affect antigen presentation. CLL cells transduced with either HSV-CD40L or hf-HSV-CD40L were compared for their ability to up-regulate B7.1 and function as T-cell stimulators in MLTR. Direct comparison of the two amplicon vectors revealed significantly better B7.1 expression in response to transduction with hf-HSV-CD40L compared to HSV-CD40L. CLL cells transduced with hf-HSV-CD40L were consistently more effective at stimulating allogeneic T-cell proliferative response than those transduced with HSV-CD40L. CLL cells transduced with helper-containing HSV amplicons showed a reduction of MHC-I expression on transduced cells, impaired capacity to respond to CD40 activation and decreased expression of CD 19 compared to cells transduced with hf-HSV amplicons. This may account for the decreased immune stimulatory function of CLL cells transduced with helper-containing HSV amplicons. We conclude that helper-free HSV amplicons represent a logical choice for immune-based clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=33748665739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748665739&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748665739

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART I

ER -